Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy, Sell, or Hold?
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$279.14 USD
-$2.12 (-0.75%)
- Volume
- 1.27M
- Average Volume
- 1.27M
- Market Capitalization
- $37.27B
- P/E Ratio
- 64.02
- Dividend Yield
- 0.00%
- Price Target
- $436.50
- Year High
- $495.55
- Year Low
- $273.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.13
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Yvonne L. Greenstreet |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALNY |
| CUSIP | 02043Q107 |
| CIK | 0001178670 |
| Web | https://www.alnylam.com |
| Phone | 617 551 8200 |
| Currency | USD |
| Employees | 2500 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.18 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.13 |
| Quick Ratio | 3.06 |
| Cash Ratio | 1.27 |
Sales & Book Value
| Annual Sales | $3.71B |
| Price / Sales | 8.69 |
| Cash Flow | 4.83 |
| Price / Cash Flow | 58.11 |
| Price / Book | 34.50 |
Price Target and Rating
| Average Stock Price Forecast | $436.50 |
| High Stock Price Forecast | $485.00 |
| Low Stock Price Forecast | $376.00 |
| Forecast Upside/Downside | -36.05% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 52 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.33 |
| Trailing P/E Ratio | 64.02 |
| PEG Ratio | 0.03 |
| P/E Growth | 0.03 |
| Net Income | $313.75M |
| Net Margin | 13.46% |
| Pretax Margin | 13.68% |
| Return on Equity | 98.29% |
| Return on Assets | 11.25% |
Financials Score
| AltmanZ Score | 5.99 |
| Piotroski Score | 7.00 |
| Working Capital | 2.87B |
| Total Assets | 5.13B |
| Ebit | 869.67M |
| Market Cap | 38.46B |
| Total Liabilities | 4.05B |
Poll Results
About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commerc ... ial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
2026-07-15 03:30:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
2026-07-13 12:25:30
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
2026-07-09 11:35:25
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
2026-07-09 07:38:00
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
2026-07-06 12:56:10
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
2026-07-02 06:33:00
The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.
2026-06-25 17:12:09
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
2026-06-25 09:00:00
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyon.
Frequently Asked Questions
-
What is the current Alnylam Pharmaceuticals, Inc. (ALNY) stock price?
-
Alnylam Pharmaceuticals, Inc.(NASDAQ:ALNY) stock price is $279.14 in the last trading session. During the trading session, ALNY stock reached the peak price of $495.55 while $273.11 was the lowest point it dropped to. The percentage change in ALNY stock occurred in the recent session was --0.75% while the dollar amount for the price change in ALNY stock was -$-2.12.
-
ALNY's industry and sector of operation?
-
The NASDAQ listed ALNY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALNY?
-
Kevin Joseph Fitzgerald | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development
Melissa McLaughlin | Chief Human Resources Officer
Phillip A. Sharp | Co-Founder, Member of the Scientific Advisory Board
Pushkal Garg | Executive VP & Chief Research & Development Officer
Bryan Andrew Supran | Chief Legal Officer -
How many employees does ALNY have?
-
Number of ALNY employees currently stands at 2500. ALNY operates from 675 West Kendall Street, Cambridge, MA 02142, US.
-
Link for ALNY official website?
-
Official Website of ALNY is: https://www.alnylam.com
-
How do I contact ALNY?
-
ALNY could be contacted at phone #617 551 8200 and can also be accessed through its website. ALNY operates from 675 West Kendall Street, Cambridge, MA 02142, US.
-
How many shares of ALNY are traded daily?
-
The average number of ALNY shares traded daily for last 3 months was 1.27M.
-
What is the market cap of ALNY currently?
-
The market value of ALNY currently stands at $37.27B with its latest stock price at $279.14